Vanberra Signal
Free trial

LungLife AI

Curated by Signal

Developer of an AI-enabled biomarker detection tests

Life Sciences Technologylunglifeai.com

Overview

LungLife AI is developing AI-enabled blood biomarker detection tests for diagnosing lung cancer. The LiquidBiopsy Platform is used to monitor and analyze the stages of lung cancer through molecular analysis of rare cells and cell-free DNA in blood samples. The platform uses next-generation sequencing (NGS), FISH and IHC for downstream molecular characterization of the cells. The platform then uses AI, machine learning and image analysis to detect lung cancer.

Key facts

Founded
2008
Headquarters
Thousand Oaks, United States
Stage
Sign up to view
Industry
Life Sciences Technology

Business model

1 product or service
Sign up to view

Contact

Phone
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

  • Eko

    Provider of AI-based remote patient monitoring platform for cardiac health

    Life Sciences TechnologyOakland, United States

  • Niraxx

    Provider of wearable device for neurological monitoring

    Life Sciences TechnologyIrvine, United States

  • GeneLinea

    Genomic comparison platform

    Life Sciences TechnologyBrea, United States

About LungLife AI

What does LungLife AI do?

LungLife AI is developing AI-enabled blood biomarker detection tests for diagnosing lung cancer.

Where is LungLife AI headquartered?

LungLife AI is headquartered in Thousand Oaks, United States.

When was LungLife AI founded?

LungLife AI was founded in 2008.

Which sector is LungLife AI in?

LungLife AI operates in Life Sciences Technology.

Who are LungLife AI's competitors?

Companies similar to LungLife AI include Eko, Niraxx, and GeneLinea.